M3V Stock Overview
Develops, markets, and sells software for recording, analyzing, and evaluating image data to manufacturers of medical devices, providers of medical IT platforms, and clinical end customers in the United States and Europe. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 4/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
My Notes
Capture your thoughts, links and company narrative
MeVis Medical Solutions AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €25.20 |
| 52 Week High | €26.40 |
| 52 Week Low | €22.40 |
| Beta | 0.0011 |
| 1 Month Change | 0.80% |
| 3 Month Change | 3.28% |
| 1 Year Change | 0.80% |
| 3 Year Change | -20.75% |
| 5 Year Change | -17.65% |
| Change since IPO | -49.60% |
Recent News & Updates
Recent updates
Shareholder Returns
| M3V | DE Healthcare Services | DE Market | |
|---|---|---|---|
| 7D | 0.8% | 1.7% | 3.0% |
| 1Y | 0.8% | -9.4% | 19.3% |
Return vs Industry: M3V exceeded the German Healthcare Services industry which returned -9.4% over the past year.
Return vs Market: M3V underperformed the German Market which returned 19.3% over the past year.
Price Volatility
| M3V volatility | |
|---|---|
| M3V Average Weekly Movement | 2.0% |
| Healthcare Services Industry Average Movement | 5.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.4% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: M3V has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: M3V's weekly volatility (2%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 100 | Marcus Kirchhoff | www.mevis.de |
MeVis Medical Solutions AG develops, markets, and sells software for recording, analyzing, and evaluating image data to manufacturers of medical devices, providers of medical IT platforms, and clinical end customers in the United States and Europe. The company's clinical focuses are image-based early detection and diagnosis of epidemiologically important diseases, such as breast, lung, liver, and neurological diseases. It offers X-ray based radiography procedures, including computed tomography, mammography/digital tomosynthesis, magnetic resonance imaging, and digital sonography; and provides services in the field of software programming for medical technology companies, which comprise provision of software developers, product and project managers, application specialists, and test engineers.
MeVis Medical Solutions AG Fundamentals Summary
| M3V fundamental statistics | |
|---|---|
| Market cap | €46.59m |
| Earnings (TTM) | €4.56m |
| Revenue (TTM) | €16.97m |
10.2x
P/E Ratio2.7x
P/S RatioIs M3V overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| M3V income statement (TTM) | |
|---|---|
| Revenue | €16.97m |
| Cost of Revenue | €10.54m |
| Gross Profit | €6.43m |
| Other Expenses | €1.87m |
| Earnings | €4.56m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
May 27, 2025
| Earnings per share (EPS) | 2.51 |
| Gross Margin | 37.91% |
| Net Profit Margin | 26.87% |
| Debt/Equity Ratio | 0% |
How did M3V perform over the long term?
See historical performance and comparisonDividends
3.7%
Current Dividend Yield34%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/19 12:26 |
| End of Day Share Price | 2025/02/19 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/09/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
MeVis Medical Solutions AG is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Michael Bissinger | Dz Bank Ag |
| FELIX ELLMANN | Warburg Research GmbH |
| Harald Hof | Warburg Research GmbH |